Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Subscribe To Our Newsletter & Stay Updated